Research Topics
Species | Ulrike Muscha SteckelingsSummaryAffiliation: Humboldt University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Advances in cardiovascular research. 15th Annual Meeting of the European Council for Cardiovascular Research (ECCR). La Colle sur Loup, France, 8–10 October 2010U Muscha Steckelings
Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
Expert Rev Cardiovasc Ther 9:21-5. 2011..This article summarizes highlights of the oral sessions, workshops and keynote lectures...
Angiotensin II type 2 receptor agonists--where should they be applied?Ulrike Muscha Steckelings
Center for Cardiovascular Research CCR, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
Expert Opin Investig Drugs 21:763-6. 2012..This article comments the review by Verdonk et al., suggests some additional possible indications, and particularly re-reviews whether there is preclinical in vivo evidence for adverse effects of AT2 receptor agonists...
AT2 receptor agonists: hypertension and beyondUlrike M Steckelings
Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Berlin, Germany
Curr Opin Nephrol Hypertens 21:142-6. 2012..This article is intending to review those publications which address AT2R function by direct in-vivo stimulation instead of indirect approaches such as receptor blockade or genetic alteration of AT2R expression...
The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targetsUlrike Muscha Steckelings
Center for Cardiovascular Research CCR, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
Fundam Clin Pharmacol 23:693-703. 2009..The present article reviews the emerging knowledge about cardiovascular and non-cardiovascular effects of the RAS with an emphasis on the mechanisms of RAS involvement and pharmacological RAS inhibition in diabetic end organ damage...
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaBFranziska Rompe
Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
Hypertension 55:924-31. 2010..These data suggest that pharmacological AT(2) receptor stimulation may be an orally applicable future therapeutic approach in pathological settings requiring the reduction of interleukin 6 or inhibition of nuclear factor kappaB...
The angiotensin AT2 receptor in left ventricular hypertrophyU Muscha Steckelings
Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, Berlin, Germany
J Hypertens 28:S50-5. 2010....
Differential expression of angiotensin receptors in human cutaneous wound healingU M Steckelings
Centre for Cardiovascular Research, Institute for Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
Br J Dermatol 153:887-93. 2005..Angiotensin AT1 and AT2 receptors are expressed in human skin. Furthermore, AT2 receptors have been reported to be upregulated during tissue repair and remodelling in various noncutaneous human tissues...
The AT2 receptor--a matter of love and hateU M Steckelings
Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
Peptides 26:1401-9. 2005..The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue...
Non-peptide AT2-receptor agonistsU Muscha Steckelings
Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
Curr Opin Pharmacol 11:187-92. 2011..In all of these models, AT2-receptor mediated anti-inflammation seemed an important underlying mechanism. C21 is awaited to enter a phase I clinical study in 2011...
HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patientsU Muscha Steckelings
Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Charite, Berlin, Germany
Blood Press 13:80-8. 2004..These insights into the causes of unsatisfactory hypertension control may help to direct future educational programmes designed to improve hypertension management specifically to these deficits and thereby to improve control rates...
The past, present and future of angiotensin II type 2 receptor stimulationU Muscha Steckelings
Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Germany
J Renin Angiotensin Aldosterone Syst 11:67-73. 2010..Moreover, it provides an overview of the first results obtained by direct AT(2) receptor stimulation with Compound 21, comprising effects on alkaline secretion, neurite outgrowth, blood pressure and post-infarct cardiac function...
Emerging drugs which target the renin-angiotensin-aldosterone systemUlrike Muscha Steckelings
Max Delbrück Center for Molecular Medicine MDC, Berlin Buch, Berlin, Germany
Expert Opin Emerg Drugs 16:619-30. 2011..The newly discovered targets have functions beyond the cardiovascular system opening up novel therapeutic areas for drugs interfering with RAAS components...
The angiotensin AT2 receptor in inflammationFranziska Rompe
Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
Drug News Perspect 23:104-11. 2010..Finally, it will give a brief outlook into new possibilities in AT(2) receptor research and in the potential utilization of AT(2) receptor stimulation as a novel pharmacological concept in anti-inflammation...
Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS componentsElena Kaschina
Center for Cardiovascular Research Institute of Pharmacology, Charite Universitatsmedizin Berlin, Germany
Atherosclerosis 205:396-403. 2009..Taken together, our data suggest that in humans, RAS activation is not just a key-player in the pathogenesis of atherosclerosis, but that a further increasing activation may be involved in the transition from atherosclerosis to AAA...
Human skin: source of and target organ for angiotensin IIU Muscha Steckelings
CCR Department of Pharmacology and Toxicology, Charite, Universitatsmedizin, Berlin, Germany
Exp Dermatol 13:148-54. 2004..These findings suggest that the complete renin-angiotensin system is present in human skin and plays a role in normal cutaneous homeostasis as well as in human cutaneous wound healing...
A long-term coculture model for the study of mast cell-keratinocyte interactionsMetin Artuc
Department of Dermatology and Allergy, Humboldt University, Charite, Berlin, Germany
J Invest Dermatol 119:411-5. 2002..The model presented here thus provides a potentially relevant tool to further clarify the interaction of dermal mast cells with major other skin cells and their contribution to cutaneous physiology, repair processes, and pathology...
Mast cell-fibroblast interactions: human mast cells as source and inducers of fibroblast and epithelial growth factorsMetin Artuc
Department of Dermatology and Allergy, Humboldt University, Charite, Berlin, Germany
J Invest Dermatol 118:391-5. 2002....
Angiotensin in the kidney: a key to understanding hypertension?Ulrike Muscha Steckelings
Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, 10115 Berlin, Germany
Cell Metab 5:7-8. 2007..However, in this experimental setting, hypertension-related left ventricular hypertrophy seemed to depend on blood pressure elevation rather than on the expression of AT1 receptors in the heart...
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?Elena Kaschina
Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
Circulation 118:2523-32. 2008..This study is the first to examine the effect of direct angiotensin II type 2 (AT(2)) receptor stimulation on postinfarct cardiac function with the use of the novel nonpeptide AT(2) receptor agonist compound 21 (C21)...
The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in strokeChrista Thone-Reineke
Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
J Hypertens 26:2426-35. 2008..We tested the effects of ceftriaxone on mortality, neurological outcome, and infarct size in experimental stroke in rats and looked for underlying mechanisms...
Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosisElena Kaschina
Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Campus Charite Mitte, Charite University Medicine Berlin, 10115 Berlin, Germany
Physiol Genomics 19:41-9. 2004..These findings suggest that genetic kininogen deficiency renders vascular tissue prone to aneurysmatic but not to atherosclerotic lesions...
